About Repros
Company Overview
Board of Directors and Management
Pipeline
Proellex
®
Anemia Associated with Uterine Fibroids
Uterine Fibroids
Endometriosis
Publications
Androxal
®
Male Fertility Maintenance/Improvement
Metabolic Syndrome
Publications
Clinical Trials
Proellex® Uterine Fibroids (ZP-005)
Proellex® Endometriosis (ZPE-201)
Proellex® Uterine Fibroids (ZPU-202)
Proellex® Uterine Fibroids - Anemia (ZPU-301)
Proellex® Uterine Fibroids (ZPU-303)
Proellex® Uterine Fibroids (ZPU-305)
Androxal® Secondary Hypogonadism (ZA-201)
Investors & Media
Events, Presentations and Webcasts
Repros in the News
Major Holders
Analyst Coverage
SEC Filings
Corporate Governance
Contact Us
Investors & Media
Events, Presentations and Webcasts
Repros in the News
Major Holders
Analyst Coverage
SEC Filings
Corporate Governance
Repros Therapeutics Inc.
$4.33 (-0.63)
Nasdaq: RPRX
Analyst
Bank
Brian Abrahams, M.D.
Oppenheimer & Co. Inc.
Matthew Kaplan
Ladenburg Thalmann & Co. Inc.
Kimberly Lee, D.O.
Pacific Growth Equities
David Martin, Ph.D., MBA
Dundee Securities
Terms of Use
� Repros Therapeutics Inc. All rights reserved.
2408 Timberloch Place, B-7
The Woodlands, Texas 77380
281-719-3400
281-719-3446 fax